 CAMBRIDGE, Mass., Nov. 17, 2020 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patients body, provided a business update for the third quarter of 2020. 